Beginning in 2012, direct oral anticoagulants (DOACs) were approved for treatment and prevention of venous thromboembolism. Prior investigations have demonstrated slow rates of adoption of novel therapeutics for black patients. We assessed the association of racial/ethnic and socioeconomic factors with DOAC use among commercially insured venous thromboembolism patients.
V
itamin K antagonists (VKA) have been used as an anticoagulant pharmacotherapy for over 60 years in the United States and until recently had been the standard therapy for venous thromboembolism (VTE). However, VKA require frequent and perpetual monitoring of the anticoagulant effect to ensure appropriate dosing, and their narrow therapeutic range despite close monitoring places patients at risk of both insufficient and excess anticoagulation, with resultant serious adverse effects. 1 In contrast, direct oral anticoagulants (DOAC) have a more predictable and stable anticoagulant effect, and thus they have become a more attractive therapeutic option. DOACs were initially used for stroke prevention in patients with atrial fibrillation (AF), with subsequent expansion of clinical indications to include the treatment and prevention of VTE after numerous studies demonstrated noninferiority or superiority of DOACs compared with VKA for VTE patients. [2] [3] [4] Beginning in 2012, these medications were approved by the US Food and Drug Administration for use in the treatment and prevention of VTE, and they are now the treatment of choice for VTE per consensus guideline recommendations. 5 Several DOACs have been introduced in the US market, including rivaroxaban in November 2012, dabigatran in April 2014, apixaban in August 2014, and edoxaban in January 2015.
To date, few studies have assessed equity in the adoption of DOACs among patients with VTE in the United States. Prior studies of technology adoption have revealed substantial disparities in access to new treatments among disadvantaged patient groups. 6, 7 In the present study, we sought to evaluate recent time trends in prescription of DOACs among a large, commercially insured population of VTE patients, and we assessed whether race and income were predictors of the likelihood of receiving DOACs versus VKA.
METHODS

Study Data
Data for this study were obtained from the OptumInsight Clinformatics Data Mart database, a large private payer administrative claims database. The database consists of inpatient, outpatient, laboratory, and pharmacy claims for a geographically diverse cohort of 13 million patients annually. Patients are predominantly located in the Midwest, South, and Southeast. Demographic and socioeconomic data, including median household income, are available through zip codelinked enrollment data from the US Census Bureau. Race and ethnicity were determined in this database through a combination of public records, self-report, and proprietary ethnicity code tables. This study used deidentified data and was considered exempt from review by the institutional review board. The methods used in this study are available from the corresponding author on reasonable request.
Study Cohort
We identified adult (ie, age >18 years) patients in the database with an index diagnosis of VTE between January 1, 2010, and December 1, 2016, who filled a prescription for an oral anticoagulant (VKA, dabigatran, rivaroxaban, edoxaban, or apixaban) within 30 days of hospital discharge. Patients were identified as having a diagnosis of VTE after a previouly validated scheme for identifying patients with VTE using administrative claims data. 8, 9 Specifically, patients were selected if they had a diagnosis of deep venous throm- Patients were excluded if they did not have continuous insurance enrollment for at least 1 year before admission for VTE, so that a complete picture of comorbidities, recent medical events, and prior anticoagulation use could be obtained for all patients. In addition, patients were required to have at least 30 days of insurance enrollment after hospital discharge for VTE, and they were required to have filled at least 1 pharmacy claim during this time period, to ensure that their pharmaceutical use was being captured in our data. Since our study was focused on patients who were being initiated on anticoagulation therapy, we excluded patients who had been treated with VKA, dabigatran, rivaroxaban, edoxaban or apixaban in the preceding year, and we excluded patients with AF, atrial flutter, antiphospholipid antibody syndrome, and prosthetic heart valves because these patients may have
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had a concomitant clinical indication for anticoagulation. We excluded patients with any VTE diagnoses within the preceding year to focus on incident diagnoses. Patients with concurrent major bleeding during the admission, as well as a diagnosis of cancer or end-stage renal disease, were likewise excluded, as their underlying condition may have influenced the choice of anticoagulant.
Statistical Analysis
Summary statistics for patient characteristics are presented as means with standard deviations for continuous data and are presented as total number and percentages for categorical data. Continuous variables were compared using the Student t test, and categorical variables were compared using the χ 2 test. To assess the relationship of race/ethnicity and socioeconomic factors to the use of DOACs, we estimated multivariable logistic regression models with the use of DOAC versus VKA as the dependent variable and with independent variables including age, sex, region of residence, zip code-linked household income, history of prior stroke, presence of an inferior vena cava filter, the Elixhauser comorbidity index, 10 and race/ethnicity. Household income categories were chosen based on available categories defined in the database. Candidate variables included in the model were selected a priori based on pathophysiological plausibility, and all were used in the multivariable model. Estimated adjusted odds ratios (ORs) are reported with 95% CI. We then estimated secondary models including interaction effects between race/ ethnicity and household income to assess for the presence of effect modification of household income on race/ethnicity by repeating the multivariable logistic regression analysis with an interaction parameter between household income and race/ ethnicity. The effect of missing data was addressed via multiple imputation analysis.
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Statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC). All statistical testing was 2-tailed, with P values <0.05 designated statistically significant.
RESULTS
A total of 14 140 patients were included in the analysis after application of exclusion criteria (Figure 1 Baseline demographic, socioeconomic, and clinical characteristics for all patients with VTE are presented in Table 1 . Overall, 10 495 (74.2%) of the patients in our cohort were treated with VKA and 3645 (25.8%) were treated with DOAC. The mean age of the cohort was 58.7 years, and 78.8% of the included patients were white, and 14.1% of the patients were black. The South and Midwest were the most highly represented areas of the country. There was a wide variety in household income, with 34.2% of the overall cohort having an annual income over $100 000 and 26.0% of patients earning <$40 000 annually.
In unadjusted analyses, patients treated with DOACs had higher household incomes, with 39.3% of patients prescribed DOAC having a household income of over $100 000, as compared with 32.4% of patients prescribed coumadin (P<0.001). There were no significant differences in congestive heart failure, hypertension, diabetes mellitus, peripheral vascular disease, or renal disease among patients prescribed VKA versus DOACs. However, there were fewer patients with prior ischemic stroke prescribed DOACs (5.7% versus 9.0%; P<0.001). There was no significant difference in the Elixhauser comorbidity count for patients prescribed DOACs as compared with VKA (P=0.12). There was a different race/ethnicity composition of patients prescribed VKA as compared with DOAC, with 14.7% of black patients prescribed VKA as compared with 12.5% who were prescribed DOACs (P=0.01).
In multivariable analyses ( with a household income over $100 000 per year were more likely to receive DOAC therapy as compared with patients with a household income of <$40 000 per year (OR, 1.50; 95% CI, 1.33-1.69; P<0.0001). Interaction testing between an income <$40 000 per year and black race was not significant (OR, 1.03; 95% CI, 0.79-1.33; P=0.84).
DISCUSSION
Since DOACs were first approved for the treatment and prevention of VTE in late 2012, there has been a steady and substantial increase in their use. However, even among a commercially insured population with prescription drug coverage, black race and lower zip code-linked household income were each independently associated with lower prescription of DOACs for incident VTE despite controlling for other socioeconomic factors. To date, this is the first study to investigate the adoption of DOACs for VTE and factors associated with persistent VKA use in a contemporary population in the United States.
DOACs were introduced for the prevention of stroke in patients in the United States with nonvalvular AF in 2010, 2 years before the approval for VTE. Previous studies among patients with AF have shown rapid rates of adoption, with 1 study finding the use of DOACs in almost 80% of patients in 2017. 12 Further, the ease of clinical use of DOACs compared with VKAs has resulted in an overall increase in the percentage of patients with AF treated with oral anticoagulation. 13 Among patients with VTE, a study of the Danish nationwide registry found that in 2016, 88% of patients were treated with DOACs, demonstrating a more rapid rate of adoption of DOACs, 14 which have concurrently been shown to be a cost-effective alternative to warfarin. 15 Although we found that the adoption of DOACs increased monotonically throughout the study period, even as late as 2016 when DOACs were in widespread clinical use, 34% of VTE patients who were eligible for DOAC therapy were still prescribed VKA in this commercially insured population. There are several possible explanations for our findings. First, there were limited options for anticoagulation reversal for DOACs when they were first introduced, unlike VKA, raising concern among treating physicians that life-threatening bleeding could be irreversible if a DOAC was used. Second, treatment with VKA necessitates frequent monitoring, allowing treating physicians to monitor medication compliance and therapeutic anticoagulation. Third, treating physicians may have been wary about the outof-pocket drug costs for their patients and preferred generic VKA. Finally, novel therapeutics are often burdened by clinical inertia, where healthcare providers may be unfamiliar with updated guidelines or unwilling to change practices. 16 Given the relatively slow rate of adoption, we sought to identify factors that were associated with the use of DOACs or warfarin and assessed whether there were racial and ethnic disparities in use.
In our study, we found that black patients with an incident diagnosis of VTE were significantly less likely to receive DOACs as compared with white patients, controlling for other socioeconomic factors. This finding was not present among Asian or Hispanic patients, although those populations were smaller, and thus our power to detect a meaningful difference in prescription rates was lower. Further, patients with lower household incomes were less likely to receive DOACs. These findings suggest the possibility of a racial inequity in access to this new pharmacotherapy, even among a population of patients with prescription drug insurance, who should face less financial pressure to choose the lowest cost therapy. Notably, there was no evidence of effect modification, because the interaction between black race and household income less than $40 000 annually was not statistically significant, which further emphasizes a major role of race in prescribing patterns.
These findings of racial/ethnic disparities are consistent with prior studies of DOAC use in AF. In a study of a prospective US-based registry of outpatients with AF, black patients were significantly less likely to receive DOACs than white patients for AF, even after controlling for clinical and socioeconomic factors. 7 In that study, there were no differences in the likelihood of prescription of DOACs between white and Hispanic patients, a finding remarkably similar to the results of our study. These findings are particularly poignant given prior data demonstrating decreased time with therapeutic international normalized ratio among black patients, possibly because of underappreciation of different dosing requirements among different racial groups. 17, 18 Racial inequities in US medical care are pervasive and well documented, 19 and there are several proposed mechanisms for racial/ethnic inequities in the treatment of black patients with cardiovascular disease in the United States. 20 Reduced access to specialty providers, including cardiologists, has been demonstrated among black patients. 21, 22 Other studies have cited differences in health insurance coverage rates to explain disparate care by race, yet we nevertheless observed racial and socioeconomic disparities in a population that was 100% insured. 23 Finally, due to the costs of DOACs, patients with lower socioeconomic status may have differential abilities to afford this medication. We did find that patients with household incomes of <$40 000 were less likely to be treated with a DOAC than patients with a household income of over $100 000. Prior studies in this population have indicated that out-of-pocket costs influence patient behaviors and compliance with medications, as the higher costs of DOACs may be prohibitive for some patients. 24 The findings of our study, as well as previous studies, raise the concern for implicit bias, or attitudes and stereotypes that affect decisions in an unconscious manner in the treatment of black patients in the United States. Studies suggest many health care providers demonstrate signs of implicit bias, with positive attitudes towards white patients and negative attitudes towards patients of color. 25 The presence of implicit bias among providers may contribute to the reduced likelihood of DOAC therapy in black patients with VTE, as they may preferentially prescribe novel, more expensive therapeutics to white patients because of perceptions of higher socioeconomic status and ability to afford the medication. 26 In addition, it has been previously demonstrated that provider interactions with patients of color are less patient-centered, with fewer requests for patient input about treatment decisions in general. 27 Prior studies have demonstrated significant heterogeneity in patient therapy preferences because of perceived differences in DOACs and VKA, which necessitates direct clarification of an individual patient's values and preferences. 28, 29 Black patients may not be given the same voice to express their preference for DOAC, especially if there are preconceived notions about preferences and ability to afford the novel therapy.
Our study has several limitations. First, the use of an administrative database provides limited granularity into the details of the circumstances surrounding individual patient care decisions, making it possible that our results were confounded by unobserved factors related to race that drove the choice of anticoagulant. To address the potential for confounding, we excluded any groups of patients that may have had underlying characteristics that altered the choice of anticoagulant therapy. However, because this study used administrative data, we were unable to observe important nonclinical variables such as patient preferences, clinician preferences/experience, prescribing provider specialty, insurance details, and clinician marketing exposure, which have been shown to influence the decision to use VKA versus DOAC. 30, 31 This choice reflects subtle and nuanced clinical decision making that may not be completely represented in a claims database. Patterns of trust in the health care system differ by race, with black patients being less likely to trust healthcare providers than white patients. 32 We must acknowledge that black patients may be less trusting of novel therapies such as DOACs, and this behavior may contribute to our findings. Second, we are also unable to study patients who were prescribed oral anticoagulants on discharge but did not fill them, as they would appear indistinguishable from patients who were never filled an oral anticoagulant prescription. Third, we were unable to study differences in outcomes between the different treatment groups because of the lack of longterm follow-up data present within the OptumInsight database. Finally, we used the race and ethnicity category as defined within the OptumInsight database. Though the race/ethnicity ascertainment methods used in this database have not been validated, self-reporting and public records, as used in this database, are often used in population-based studies of race and ethnicity. Further, the categories present do not fully capture the many races and ethnicities present in the United States. Disparities within broad groups may not be fully represented. More importantly, the operationalization of race in a broader socioeconomic and sociopolitical context, the effects of structural racism, patients' experience with the healthcare system and levels of perceived racism are not fully captured. However, despite the aforementioned limitations, and given the demonstrated benefit of DOACs as compared with VKA in the treatment of VTE, the finding of reduced use of use of DOAC among these patients highlights the importance of efforts to improve equitable medication uptake and utilization among all racial, ethnic, and socioeconomic groups.
CONCLUSIONS
We found a consistent and substantial increase in the use of DOACs among patients with VTE in the United States. However, in this fully insured patient population, black race and lower zip code-linked household income were each independently associated with lower use of DOACs for incident VTE. These findings suggest the presence of both racial and socioeconomic inequity in access to this novel pharmacotherapy.
